SAMDaily.us | AWARD | A | Phase 2b Clinical Trial to develop a next-generation, mucosally delivered, COVID-19 booster vaccine capable of eliciting mucosal immunity and protecting against SARS-CoV-2 breakthrough infection and transmission.

SAMDAILY.US - ISSUE OF SEPTEMBER 30, 2023 SAM #7977
AWARD

A -- Phase 2b Clinical Trial to develop a next-generation, mucosally delivered, COVID-19 booster vaccine capable of eliciting mucosal immunity and protecting against SARS-CoV-2 breakthrough infection and transmission.

Notice Date: 9/28/2023 12:20:30 PM
Notice Type: Award Notice
NAICS: 541714 — Research and Development in Biotechnology (except Nanobiotechnology)
Contracting Office: ASPR OFFICE OF THE ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE Washington DC 20201 USA
ZIP Code: 20201
Solicitation Number: BAA-18-100-SOL-00003
Archive Date: 10/12/2023
Point of Contact: Kathleen Sears, Phone: 2027447667
E-Mail Address: kathleen.sears@hhs.gov
(kathleen.sears@hhs.gov)
Award Number: 75A50123C00065
Award Date: 09/27/2023
Awardee: CASTLEVAX INC New York NY 10014 USA
Award Amount: 398973027.00
Description: This is a competitively awarded hybrid firm fixed priced and cost reimbursement contract for a Phase 2b efficacy study to develop a next-generation, mucosally delivered, COVID-19 booster vaccine capable of eliciting mucosal immunity and protecting against SARS-CoV-2 breakthrough infection and transmission. The contract award amount is $398,973,027.
Web Link: SAM.gov Permalink
(https://sam.gov/opp/3d1222c61ac04a3eb79b4e6e53872a46/view)
Place of Performance: Address: New York, NY 10014, USA; Zip Code: 10014; Country: USA
Record: SN06847398-F 20230930/230928230043 (samdaily.us)
Source: SAM.gov Link to This Notice
(may not be valid after Archive Date)

| FSG Index | This Issue's Index | Today's SAM Daily Index Page |